Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 19.
doi: 10.1007/s10728-024-00497-9. Online ahead of print.

The Epistemic Policies of Anti-Ageing Medicines in the European Union

Guillermo Marín Penella  1
Affiliations

The Epistemic Policies of Anti-Ageing Medicines in the European Union

Guillermo Marín Penella. Health Care Anal. .

Abstract

Anti-ageing medicines are products intended to extend lifespan and healthspan in humans that have a good potential use in public health policies. In the European Union, their development, production and consumption are dependent on regulatory science performed by the European Medicines Agency and its associated epistemic policies. They impose, among other things, an unfavourable burden of proof, a strict standard of proof and meta-methodological constrictions related to some theoretical issues. This results in a distribution of errors that tends to reduce false positives while increasing false negatives, leading to a set of social consequences that are generally accepted when the focus is placed on conventional medicines. However, when the same epistemic policies are applied to anti-ageing medicines, the distribution of errors is imbalanced, and undesirable outcomes like research discouragement and waiting time extensions appear. Three possible strategies that policymakers could implement to unblock the situation are presented for future reflection: the consideration of ageing as a disease, the application of methodological asymmetry and the use of biomarkers during clinical research.

Keywords: Anti-ageing medicines; Epistemic policies; European Medicines Agency; Policymaking; Regulatory science.

PubMed Disclaimer

Conflict of interest statement

Declarations Competing Interests The author has no relevant financial or non-financial interests to disclose.

Similar articles

See all similar articles

References

    1. Roser, M., Ortiz-Ospina, E., & Ritchie, H. (2013). Life expectancy. Our World in Data. Retrieved December 5, 2022, from https://ourworldindata.org/life-expectancy
    1. Sinclair, D., & LaPlante, M. (2019). Lifespan: why we age and why we don’t have to. Thorsons.
    1. Stanford Centre on Longevity (2022). The new map of life. Stanford Centre on Longevity. Retrieved December 5, 2022, from https://longevity.stanford.edu/the-new-map-of-life-full-report/
    1. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243–278. https://doi.org/10.1016/j.cell.2022.11.001 - DOI - PubMed
    1. Mishra, S. K., Balendra, V., Esposto, J., Obaid, A. A., Maccioni, R. B., Jha, N. K., Perry, G., Moustafa, M., Al-Sheri, M., Singh, M. P., Khan, A. A., Vamanu, E., & Singh, S. K. (2022). Therapeutic antiaging strategies. Biomedicines, 10(10). https://doi.org/10.3390/biomedicines10102515

LinkOut - more resources

  NODES
Project 1
twitter 2